Cala Health

Cala Health is a neurotechnology company headquartered in Burlingame, California, developing innovative solutions in the neuromodulation space. The company's flagship product, Cala Trio, is a wrist-worn device that delivers personalized peripheral nerve stimulation therapy for patients suffering from essential tremor. Cala Trio works by detecting individual patient tremor frequencies and delivering precisely calibrated transcutaneous stimulation through the wrist, offering a non-invasive alternative to traditional treatment approaches. The device represents a significant advancement in precision medicine by tailoring therapy to each patient's unique neurological signature.

Cala Health has demonstrated strong market traction and investor confidence, having raised $77 million in Series C funding to support clinical validation, regulatory approval, and commercialization efforts. The company's focus on essential tremor addresses a substantial patient population with limited effective treatment options, positioning Cala Health as a key player in the emerging peripheral nerve stimulation market. By combining wearable technology with targeted neuromodulation, Cala Health has attracted significant attention from both the medical device and venture capital communities.

The company is reshaping the neurotech landscape by proving that wearable peripheral nerve stimulation can deliver therapeutic outcomes for neurological conditions without the risks and invasiveness of surgical interventions like deep brain stimulation. Cala Health's data-driven approach to personalizing stimulation parameters sets a new standard for precision neurotechnology and demonstrates the potential for non-invasive, patient-centric neuromodulation therapies. As the neurotech industry increasingly emphasizes accessibility and non-invasiveness, Cala Health's work represents an important validation of wearable-based approaches to treating previously challenging neurological disorders.